Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 15/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13587406 | 0.84 | P2RX7 (0.61) | P2RX7P2RX3 | |
| SCHEMBL13587418 | 0.81 | P2RX7 (0.60) | P2RX7MEN1USP2KMT2A | |
| SCHEMBL13587413 | 0.81 | P2RX7 (0.57) | P2RX7P2RX3 | |
| SCHEMBL4140355 | 0.79 | P2RX7 (0.63) | P2RX7MEN1USP2KMT2ASMN1; SMN2 | |
| SCHEMBL4141042 | 0.79 | P2RX7 (0.71) | P2RX7P2RX3 | |
| SCHEMBL4137913 | 0.79 | P2RX7 (0.60) | P2RX7MEN1USP2KMT2ASMN1; SMN2 | |
| SCHEMBL13587411 | 0.78 | KDM4E (0.51) | P2RX7P2RX3 | |
| SCHEMBL4139538 | 0.78 | P2RX7 (0.73) | P2RX7MEN1USP2KMT2ASMN1; SMN2 | |
| SCHEMBL4142230 | 0.78 | P2RX7 (0.69) | P2RX7MEN1USP2KMT2AP2RX3 | |
| SCHEMBL13587408 | 0.78 | P2RX7 (0.57) | P2RX7P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298825-A1 | Bicycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof | RENOVIS, INC. | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298825-A1 | Bicycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX1 | P2RX7 1/4885MEN1 4837/4885USP2 4764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.